1 / 4

Smart Insulin or Glucose Responsive Insulin Market By Type, Disease, And Delivery Device - Global Industry Analysis And

Diabetes is a disease in which the body either doesn't make enough insulin or can't utilize the produced insulin. Indiabetesblood glucose level is high. Polyuria, polydipsia, polyphagia, dry skin and tingling sensation in hands or feet are symptoms of diabetes

sunnyyadav
Download Presentation

Smart Insulin or Glucose Responsive Insulin Market By Type, Disease, And Delivery Device - Global Industry Analysis And

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Smart Insulin or Glucose Responsive Insulin Market By Type, Disease, And Delivery Device - Global Industry Analysis And Forecast To 2025 Diabetes is a disease in which the body either doesn't make enough insulin or can't utilize the produced insulin. Indiabetesblood glucose level is high. Polyuria, polydipsia, polyphagia, dry skin and tingling sensation in hands or feet are symptoms of diabetes. There are three types of diabetes, namely, type 1 (insulin dependent), type 2 diabetes (insulin independent) and gestational diabetes. In type 1 diabetes, the part of pancreas is attacked by body’s immune system. By mistake, the immune system destroys isletsin the pancreas assuming them as foreign particles. The islets are the insulin producing cells. Causes for type 1 diabetes are diseases of the pancreas, infections and family history. In type 2 diabetes, insulin is produced in less quantity but it’s not enough to maintain optimum blood glucose. Causes of type 2 diabetes are obesity or overweight, ethnicity, gestational diabetes, age, sedentary lifestyle, impaired glucose tolerance, family history and insulin resistance. Gestational diabetes develops only during pregnancy. Diabetes is controlled by delivering insulin or with the help of antidiabetic drugs. Insulin is released by the beta cells in response to the high blood glucose levels. Insulin thus allows maintenance of blood glucose level in optimum range. In type 1-diabetes, the body no longer produces enough insulin as beta cells are destroyed. Thus controlling the blood sugar level is challenging aspect in management of type 1 diabetes. In such a case smart insulin can be used. A perfect glucose control will be maintained by smart insulin. Smart insulin or glucose responsive insulin has ability to circulate in the body. It would respond automatically to level of blood glucose in the body. It can turn on when it’s needed and off when it’s not needed. If the blood glucose is higher, more insulin will be released or activated. If the blood glucose level is lower, less insulin will be released. Smart insulin will avoid the complications related to high and low blood sugar levels. It will reduce the requirement of checking the blood glucose level regularly. It will also reduce the efforts of calculating insulin doses and multiple daily injections. Smart insulin will give confidence to type 1 diabetes patients, that to cover their needs for the day they have enough insulin no matter how rigorously they work, what or how stressed they are. Browse full research report with TOC on “Smart Insulin or Glucose Responsive Insulin Market By Type, Disease, And Delivery Device - Global Industry Analysis And Forecast To

  2. 2025” at:http://www.crystalmarketresearch.com/report/smart-insulin-or-glucose- responsive-insulin-market The major driving factor for the smart insulin market is increase in diabetic population. For instance, according to IDF, in 2015, diabetes affected 415 million people worldwide and this number is expected to reach up to 642 million by 2040. Moreover, it was found that one in 11 adults was suffering from diabetes. Moreover, rise in the collaboration of companies with research institutions will further drive this market. For instance in March 2016, JDRF and Sanofi announced expansion of their joint research collaboration to include development of glucose responsive insulin therapies for treatment of insulin dependent diabetes. The aim of this collaboration is to design therapeutic insulin which gets activated when blood-glucose levels rise and deactivated when blood-glucose levels begin to go low, thus preventing dangerous highs and lows. Moreover, technological improvements in the insulin delivery devices will also contribute to growth of this market. Further, insulin injections are painful and thus there is a rise in demand by people for alternatives such as smart insulin. This demand will boost the smart insulin market. Furthermore, smart insulin patch will serve as an opportunity for this market. The smart insulin patch will use painless microneedles to recognize the low oxygen environment which will be created when glucose levels rise. Further, it will deliver insulin as required. However, more complexities are associated in manufacturing of smart insulin which will impede the growth of smart insulin market. Moreover, huge investment cost in developing smart insulin andstrict regulatory requirements for approvalswill also hamper the growth of this market. The key strategy followed by the major companies is acquisition to be a pioneer in this market, as smart insulin is a new market and players are looking to gain competitive advantage. For instance, in 2016, Eli Lilly and Company acquired Glycostasis, Inc. Glycostasis, Inc. invented a new technology known as smart insulin. This technology will help in regulating blood glucose level by releasing more insulin when blood glucose level is high and less insulin when blood glucose level is low. By this acquisition, Eli Lilly and Companywill become a pioneer in the smart insulin or glucose responsive insulin market. The major players inthe smart insulin or glucose responsive insulin market are Sanofi, Novo Nordisk A/S, Juvenile Diabetes Research Foundation Ltd., Eli Lilly and Company, and Merck & Co., Inc. Request for TOC of Smart Insulin or Glucose Responsive Insulin Market Research Report @ http://www.crystalmarketresearch.com/request-toc/upcoming/HC0665 Smart Insulin or Glucose Responsive Market Segmentation:

  3. By Type: Intermediate Acting Short Acting Premixed Type Long Acting Rapid Acting By Disease: Type 1 Diabetes Type 2 Diabetes By Delivery Device: Smart Insulin Patch or Microneedle Array Patch Smart Insulin Pen Smart Insulin Pump Download PDF Brochure @http://bit.ly/2A9jvzL About Crystal Market Research Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy. Contact: Judy 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States

  4. Toll Free: +1-888-213-4282 Email: sales@crystalmarketresearch.com Blog: https://blog.crystalmarketresearch.com Website: http://www.crystalmarketresearch.com Connect with us: LinkedIn | Twitter | Facebook

More Related